Seaport Therapeutics (SPTX) Q1 2026 earnings summary

Executive summary

• Clinical-stage therapeutics company focused on neuropsychiatric disorders, leveraging the proprietary Glyph platform to develop oral therapies for depression, anxiety, and related conditions.

• Advanced clinical development of lead programs GlyphAllo and GlyphAgo, with new Phase 1 data supporting safety and efficacy profiles.

• Lead candidate GlyphAllo is in Phase 2b for major depressive disorder (MDD); topline data expected in 1H 2027. GlyphAgo, targeting generalized anxiety disorder (GAD), completed Phase 1 with strong bioavailability and safety data; Phase 2 trials planned.

• Completed IPO in Q2 2026, raising $238.7 million in net proceeds ($260M gross), following $326.1 million in prior private financings.

• Appointment of Dr. Sharon Mates to Board, bringing significant neuropsychiatry leadership experience.

Financial highlights

• Net loss for Q1 2026 was $25.4 million, up from $13.1 million in Q1 2025, driven by increased R&D and G&A expenses.

• Operating expenses rose to $27.5 million from $16.2 million year-over-year, with R&D expenses increasing by $10.9 million to $21.4 million.

• Cash, cash equivalents, and investments totaled $212.6 million as of March 31, 2026; post-IPO, total funding supports operations into 2029.

• No revenue generated from product sales; company remains pre-commercial.

• G&A expenses increased to $6.1 million from $5.7 million year-over-year, mainly due to personnel costs.

Outlook and guidance

• Existing cash and IPO proceeds expected to fund operations into 2029 based on current plans.

• Anticipates continued increases in R&D and G&A expenses as clinical programs advance and public company costs rise.

• Expects to initiate multiple Phase 2 trials for GlyphAgo in 2027-2028 and continue preclinical development of additional candidates.

• Topline data from Phase 2b BUOY-1 trial for GlyphAllo in MDD expected 1H 2027; Phase 1 driving simulation trial for GlyphAllo to report data in 2H 2026.

• Phase 2a proof-of-pharmacology trial for GlyphAgo in GAD and sleep disturbance to start 2H 2026, topline data in early 2028.